Cooper Maroc - Pharmaceutical Drug Production, Out-Licensing and In-Licensing

Cooper Maroc Pharmaceuticals is a leading Moroccan pharmaceutical company that manufactures, imports and distributes various pharmaceutical formulations. Cooper Maroc manufactures and exports a wide range of products, both under its own name and for its various partners all over the world. The company generated $150 million in 2006.

Cooper Maroc Pharmaceuticals' headquarters are in Casablanca, Morocco, and have a state-of-the-art facility that manufactures capsules, syrups, tablets, sterile injections, ointments, etc. The facilities are c-GMP compliant and in the process of being certified by the French regulatory agency, AFSSAPS. The main facility has exported products to Norway and Denmark since 2000.

REGIONAL PHARMACEUTICAL DRUG PRODUCTION

Cooper Maroc's vision is to be a respected reference and leader on the regional pharmaceutical drug production market, by developing branded generics, as well as constructing other licensee's products in this area.

Cooper Maroc has four main strategic businesses:

• Distribution activity
• Branded generics activity
• In-licensing activity
• Out-licensing and export activity

BRANDED GENERICS PORTFOLIO

Cooper Maroc has built an extensive branded generics portfolio. The products are developed with partners from all over the world (mostly Europe and Asia). The company's know-how in local registration speeds up the regulatory process.

The effectiveness of our sales and marketing team allows Cooper Maroc to build strong pharmaceutical brands in competitive therapeutic areas such as cardiology and gastrology. The total sales-force is reaching 120 sales representatives for doctors, and 10 sales representatives for pharmacies' OTC trade.

PHARMACEUTICAL PRODUCT DISTRIBUTION

Cooper Maroc is the leader in Morocco regarding the distribution of pharmaceutical products. With more than six subsidiaries all over the kingdom, the company is the best distributor for all manufacturing and importing pharmaceutical firms present in the territory. Cooper's distribution and logistics branch has a 20% share of the domestic market.

PHARMACEUTICAL EXPORT AND OUT-LICENSING

In the current and future context of globalisation, Cooper Maroc Pharmaceuticals focuses its strategy on the external market, thus regarding out-licensing as an indication of development and competitiveness.

This strategy is based on:

• Permanent levelling of manufacturing equipment (c-GMP, US FDA and EU approval)
• Adaptation of products and services to external markets (adapted portfolios, adequate marketing and medical support)
• Regulatory files for the health agencies filing, assembled according to the latest European standards
• Commercial reactivity

Cooper Maroc products are present in more than 20 countries.

MULTINATIONAL LABORATORY IN-LICENSING

Cooper Maroc represents, under license, more than 100 specialities for 20 multinational laboratories (including Abbott, Almirall, Mayoly, P. Fabre, Organon, Pfizer, GSK, Daiichi Sankyo and Novartis Ophtalmics).

Cooper Maroc builds its activities on successful partnerships, in sales, marketing, 'toll manufacturing' and licence agreements, with other pharmaceutical companies. These companies – which are of variable size and world origin, and have different strategies – find in Cooper Maroc their exclusive representative in Morocco, and sometimes even in other French-speaking African countries and the Middle East.

Eastern Europe and France are currently under advanced inspection with regards to prospective business.